BioMed Research International / 2015 / Article / Tab 2

Research Article

Expression of HE4 in Endometrial Cancer and Its Clinical Significance

Table 2

HE4 expression in endometrial cancer with different clinical parameters.

FeaturesCasesPositive casesPositive
rate (%)
Strong positive
cases
Strong
positive
rate (%)

EC typeI282382.141553.57 0.456 0.747
II746587.843750.00

Pathological typeEndometrial adenocarcinoma494591.842653.06
Uterine papillary serous carcinoma211571.43838.10
Clear cell carcinoma221986.361150.00
Mucous carcinoma44100.00375.00
Undifferentiated carcinoma3266.67266.67
Squamous cell carcinoma22100.00150.00
Small cell carcinoma11100.001100.00

FIGO stageIa
Ib
II
III
IV
38
23
7
28
6
29
21
5
27
6
76.32
91.30
71.43
96.43
100
12
13
2
20
5
31.57
56.52
28.57
71.42
83.33




Others



7 



Others

Differentiation  
level
High221672.72934.62
Others
Middle282485.711346.43
Low524892.313057.69

Lymphatic metastasisNo594881.362259.46
Yes272696.302177.78
No lymph node cleaning161487.50956.25

Note: of HE4 positive rate in each group; of strongly positive HE4 expression rate in each group.